1933 Industries 株価情報 (OTC: TGIFF)

最新ニュース 1933 Industries (OTC:TGIFF) 株価情報

1933 Industries

1933 Industries Inc is a vertically integrated cannabis company. The company is focused on the cultivation and manufacturing of cannabis consumer-branded goods. The Company operates in three segments, referred to as AMA, Infused MFG, and Corporate. AMA is focused on the cultivation and sale of medical and adult-use cannabis products, and Infused MFG is focused on the manufacturing of hemp-derived CBD products. The majority of revenue is generated from the AMA segment. The operations of AMA and Infused MFG are located in the United States. All revenues are earned in the United States.

1933 Industries Inc

Edward Smolyansky, who together with Ludmila Smolyansky, beneficially own approximately 27% of outstanding shares of Lifeway Foods common stock, today issued the following statement in response to Lifeway's amended 2024 Annual Report and its latest disclosures on executive and director compensation.
Apparent Delay of 2025 Annual Meeting of Shareholders
On March 13, Edward Smolyansky submitted a full slate of Board nominees for Lifeway's 2025 Annual Meeting. To date, Lifeway has yet to file a preliminary or definitive proxy statement setting forth its own slate.
"The filing of the amended 2024 Annual Report, and other steps taken recently by the Company, suggest to me that the Board is planning to delay the 2025 Annual Meeting of Shareholders past the June 2, 2025, date provided for in the bylaws," said Mr. Smolyansky. "I am prepared to make my case to our fellow shareholders - at the annual meeting or otherwise - and it is disappointing that the Board is not prepared to do the same."
Any attempt to delay the annual meeting or sidestep the proxy contest would reflect yet another act of hostility toward shareholders, led by CEO/Chair Julie Smolyansky and endorsed by an entrenched and ineffective Board.
The Company is clearly at an inflection point as shareholders rightly question whether the Board's rejection of Danone's offer –&nbsp;at a significant premium to the then-current share price – served the interests of directors and executives over those of shareholders, especially given the hostile actions toward Danone and the exorbitant compensation awarded to Julie Smolyansky in the immediate aftermath.
In December 2024, the Board awarded Ms. Smolyansky a $2 million retention bonus and a $6.5 million equity grant1&nbsp;without providing any rationale in Lifeway's updated compensation disclosures. It also quietly increased her change-in-control severance multiple from 2x to 3x her base salary. These rewards came in a year when Lifeway's earnings declined by 20.6%.
Legal and Regulatory Dysfunction
Under Ms. Smolyansky's leadership, Lifeway has initiated multiple lawsuits against its largest shareholders, including Edward and Ludmila Smolyansky. These legal actions raise questions about governance, internal controls, and the misuse of shareholder funds. They also potentially undermine Lifeway's standing and influence in future court proceedings.
The company has been embroiled in multiple legal disputes, including a federal trade infringement lawsuit against former executives Edward and Ludmila Smolyansky along with their new venture, Pure Culture Organics&#x2122; that was dismissed with prejudice, permanently barring Lifeway from bringing the same claim again. Perhaps more troubling, Burdeen's multiple false declarations in the case have eroded Lifeway's credibility in court, while his broader involvement has significantly weakened the company's legal and strategic standing.
"Julie would rather spend her time –&nbsp;and shareholders' dollars –&nbsp;suing her own family than leading Lifeway through today's volatile economy," said Edward Smolyansky. "Every lawsuit filed against me has either been dismissed, dropped, or defeated. The Board should not be enabling such meritless, retaliatory legal actions."
To date, Lifeway has spent over $1 million pursuing legal claims against Edward Smolyansky, with no return for shareholders – an expense that calls into question the Board's legal oversight and risk management processes.
No Legal Department –&nbsp;But a "Chief of Staff" Acting as One
In January 2020, Lifeway eliminated its entire internal legal department, including the senior position of General Counsel. Since then, the company has relied exclusively on outside counsel for its aggressive legal efforts –&nbsp;again, at great cost to shareholders.
With no legal team in place, Jason Burdeen, CEO Julie Smolyansky's husband and Chief of Staff, has assumed wide-ranging control over legal matters. Burdeen holds no law degree, no legal training, and no relevant background in compliance or corporate governance. Despite this, he has exercised influence over nearly every aspect of Lifeway's operations, including its legal strategy, personnel decisions, and internal oversight.
According to Lifeway's 10-K/A filed April 29, despite not holding a formal employment agreement, Burdeen received a total compensation package of $313,800 in 2024 – 30% more than the year before. This included a $100,000 "short-term incentive cash bonus." Lifeway has neglected to explain what warranted that bonus.
"Shareholders deserve to know whether that bonus was awarded for performance, or for consolidating control and absorbing responsibilities once held by Lifeway's former General Counsel and Senior EVP of Sales," said Edward Smolyansky.
Ironically, Lifeway's own governance policy instructs employees to report concerns to the General Counsel or legal department, neither of which currently exists.
Warranted Change is Imminent
While the Board continues to stall and evade accountability, Edward and Ludmila Smolyansky are determined to continue pressing Lifeway to immediately set a date for the 2025 Annual Meeting and proceed with director elections as required.

News

LWAY

Edward Smolyansky, Together With Ludmila Smolyansky, Who Beneficially Own ~27% Of Outstanding Shares Of Lifeway Foods Common Stock, Issues Statement In Response To Lifeway's Amended 2024 Annual Report

Stephens &amp; Co. analyst Trey Grooms maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Overweight and lowers the price target from $145 to $140.

Price Target

Analyst Ratings

BLDR

Stephens & Co. Maintains Overweight on Builders FirstSource, Lowers Price Target to $140

Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) has outperformed the market over the past 15 years by 4.57% on an annualized basis producing an average annual return of 15.74%. Currently, Micron Technology has a market capitalization of $91.00 billion. 
Buying $100 In MU: If an investor had bought $100 of MU stock 15 years ago, it would be worth $949.94 today based on a price of $81.43 for MU at the time of writing.
<h3>Micron Technology's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746205016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Micron Technology Stock In The Last 15 Years

Goldman Sachs analyst Paul Choi maintains Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) with a Neutral and lowers the price target from $10 to $5.

PHAT

Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $5

Insider Trades

Reported May, 1 2025: Lifeway Foods Form4 Filing Shows Ludmila Smolyansky Sold 20,518 Shares At An Average Price Of $23.77/Share

Stephens &amp; Co. analyst Terry McEvoy maintains First Mid Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMBH#NASDAQ">FMBH</a>) with a Equal-Weight and lowers the price target from $43 to $41.

FMBH

Stephens & Co. Maintains Equal-Weight on First Mid Bancshares, Lowers Price Target to $41

Goldman Sachs analyst Brooke Roach maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Sell and raises the price target from $4 to $4.5.

Goldman Sachs Maintains Sell on Kohl's, Raises Price Target to $4.5

Goldman Sachs analyst Matthew Sykes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $180 to $160.

ICLR

Goldman Sachs Maintains Neutral on Icon, Lowers Price Target to $160

Stephens &amp; Co. analyst Mason Carrico maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and lowers the price target from $140 to $115.

GKOS

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $115

Goldman Sachs analyst Lizzie Dove maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Sell and raises the price target from $110 to $123.

Goldman Sachs Maintains Sell on Hyatt Hotels, Raises Price Target to $123

Goldman Sachs analyst Noah Poponak maintains Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) with a Buy and raises the price target from $236 to $265.

Goldman Sachs Maintains Buy on Huntington Ingalls Indus, Raises Price Target to $265

Shares of Polyrizon Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) surged 223% to 82 cents Friday afternoon, following a reversal in reverse stock split plans from Thursday.
What To Know: On Thursday morning, the company had announced a <a href="https://investor.polyrizon-biotech.com/pdfcontent/cik/1893645/id/d0555c49-8cb2-4fbd-9c9f-df32cb0bbfe3/file/ea0240173-6k_polyrizon.htm/to/000121390025038043_ea0240173-6k_polyrizon.pdf">1-for-10 reverse stock split</a>, intended to consolidate every ten shares into one, with trading on a post-split basis to begin May 5. The move originally aimed to bolster the company's per-share price, a common tactic to meet minimum listing requirements. 
However, late Thursday, Polyrizon <a href="https://investor.polyrizon-biotech.com/pdfcontent/cik/1893645/id/f7b4ddc3-bd8e-4976-9012-7c56b7348467/file/ea0240537-6k_polyrizon.htm/to/000121390025038530_ea0240537-6k_polyrizon.pdf">canceled the reverse split</a>, stating it would not proceed with the plan as previously disclosed. 
The change has triggered a flurry of speculative trading during Friday&#8217;s session, as the company provided no further explanation for the decision, leaving investors to interpret the implications. 
Friday&#8217;s volatility also highlights the sensitivity of small-cap stocks to corporate actions and the potential impact of sudden governance shifts.
Read Also: <a href="https://www.benzinga.com/25/05/45168400/apple-stock-falls-after-cook-warns-of-900m-tariff-impact">Apple Stock Falls After Cook Warns of $900M Tariff Impact</a>
<h2 class="wp-block-heading">How To Buy PLRZ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Polyrizon&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLRZ has a 52-week high of $4.80 and a 52-week low of $0.25.

PLRZ

Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On?

Stephens &amp; Co. analyst Terry McEvoy maintains Finward Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWD#NASDAQ">FNWD</a>) with a Overweight and raises the price target from $32 to $34.

FNWD

Stephens & Co. Maintains Overweight on Finward Bancorp, Raises Price Target to $34

Goldman Sachs analyst Lizzie Dove maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Sell and raises the price target from $30 to $34.

Goldman Sachs Maintains Sell on Hilton Grand Vacations, Raises Price Target to $34

Goldman Sachs analyst Neil Mehta maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and lowers the price target from $27 to $24.

Goldman Sachs Maintains Buy on Halliburton, Lowers Price Target to $24

Stock Split

Reported May 1, 2025: Polyrizon Announced The Planned Reverse Share Split Of The Company's Ordinary Shares At The Ratio Of 1-For-10 That Was Previously Announced On May 1, 2025, Will Not Be Effectuated

Stephens &amp; Co. analyst Matt Olney maintains Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) with a Equal-Weight and raises the price target from $138 to $141.

Stephens & Co. Maintains Equal-Weight on Cullen/Frost Bankers, Raises Price Target to $141

Goldman Sachs analyst Kate McShane maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Sell and lowers the price target from $81 to $70.

Goldman Sachs Maintains Sell on Floor & Decor Hldgs, Lowers Price Target to $70

Goldman Sachs analyst Will Nance maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Buy and lowers the price target from $65 to $57.

Goldman Sachs Maintains Buy on Block, Lowers Price Target to $57

Stephens &amp; Co. analyst Brett Huff maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Equal-Weight and lowers the price target from $255 to $221.

Comments

1933 Industries

ニュース

最新ニュース 1933 Industries (OTC:TGIFF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル